Kenneth Sumner, MD
Psychiatry · Metairie, LANPI 1073653275
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 629 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 629 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Lundbeck LLC$1K
- Alkermes, Inc.$934
- Johnson & Johnson$879
- Axsome Therapeutics, Inc.$855
- plus $5K from 21 others
What the payments were for
- Food & beverage$11,600100%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 116 | $2,153 |
| Otsuka America Pharmaceutical, Inc. | 55 | $1,108 |
| Lundbeck LLC | 56 | $1,011 |
| Alkermes, Inc. | 44 | $934 |
| Johnson & Johnson | 52 | $879 |
| Axsome Therapeutics, Inc. | 38 | $855 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 53 | $627 |
| Tris Pharma Inc | 34 | $588 |
| Supernus Pharmaceuticals, Inc. | 17 | $520 |
| Teva Pharmaceuticals USA, Inc. | 31 | $442 |
| Almatica Pharma LLC | 23 | $434 |
| Vanda Pharmaceuticals Inc. | 19 | $375 |
| Neurocrine Biosciences, Inc. | 12 | $338 |
| Noven Therapeutics, LLC | 20 | $317 |
| Corium, LLC | 16 | $258 |
| Idorsia Pharmaceuticals US Inc | 13 | $170 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $140 |
| Shire North American Group Inc | 7 | $125 |
| Bausch Health US, LLC | 5 | $90 |
| Acadia Pharmaceuticals Inc | 3 | $57 |
| Bioxcel Therapeutics, Inc. | 3 | $54 |
| Jazz Pharmaceuticals Inc. | 1 | $28 |
| Brainsway USA Inc | 1 | $24 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $24 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$104
How this compares
$11,603 in reported general payments places this provider in the 95th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 30 | $52,575 |
| VraylarCariprazine Hcl | 23 | $35,300 |
| VyvanseLisdexamfetamine Dimesylate | 24 | $9,347 |
| Bupropion XlBupropion Hcl | 279 | $7,709 |
| Lisdexamfetamine Dimesylate | 21 | $5,537 |
| Clozapine | 68 | $4,224 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 209 | $3,977 |
| Vilazodone Hcl | 20 | $3,583 |
| Trazodone Hcl | 325 | $3,272 |
| Fluoxetine Hcl | 297 | $2,620 |
| Duloxetine Hcl | 123 | $2,495 |
| Sertraline Hcl | 219 | $1,946 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 85 | $1,902 |
| Quetiapine Fumarate | 62 | $1,808 |
| Memantine Hcl | 78 | $1,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,108 | $52,57530 claims |
| AbbVieVraylar | $2,153 | $35,30023 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $140 | $9,34724 claims |
| Almatica Pharma LLCSertraline Hcl | $434 | $1,946219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 psychiatry providers in Louisiana.
Other psychiatry in Metairie
- Charles ChesterMetairie$14K
- Teri SchwarzMetairie$13K
- Julie CeasarMetairie$12K
- Jonathon RynningMetairie$11K
- Sidney SmithMetairie$10K
- Jose RodriguezMetairie$9K
- Patrick HayesLake Charles$837K
- Maria CruseThibodaux$522K
- Larry WarnerBaton Rouge$495K
- Gregory BrownShreveport$495K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.